Trending Stock News

$-1.74 EPS Expected for Spark Therapeutics, Inc. (ONCE); Willbros Group (WG) Sentiment Is 2.24

Willbros Group, Inc., through its subsidiaries, operates as a specialty energy infrastructure contractor serving gas and oil, and power industries in the United States and Canada. The company has market cap of $61.96 million. The firm operates through three divisions: Oil & Gas, Utility T&D, and Canada. It currently has negative earnings. The Oil & Gas segment offers construction, maintenance, and lifecycle extension services to the midstream markets.

Analysts expect Spark Therapeutics, Inc. (NASDAQ:ONCE) to report $-1.74 EPS on February, 28.They anticipate $0.52 EPS change or 42.62% from last quarter’s $-1.22 EPS. After having $-1.90 EPS previously, Spark Therapeutics, Inc.’s analysts see -8.42% EPS growth. The stock decreased 0.89% or $0.49 during the last trading session, reaching $54.5. About 472,492 shares traded. Spark Therapeutics, Inc. (NASDAQ:ONCE) has risen 13.53% since February 17, 2017 and is uptrending. It has underperformed by 3.17% the S&P500.

Among 24 analysts covering Spark Therapeutics (NASDAQ:ONCE), 15 have Buy rating, 2 Sell and 7 Hold. Therefore 63% are positive. Spark Therapeutics had 62 analyst reports since August 21, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained the stock with “Buy” rating in Wednesday, January 24 report. Stifel Nicolaus maintained the stock with “Buy” rating in Tuesday, October 10 report. The stock has “Buy” rating by Jefferies on Wednesday, August 2. The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) has “Buy” rating given on Tuesday, April 12 by Evercore. Leerink Swann downgraded Spark Therapeutics, Inc. (NASDAQ:ONCE) on Tuesday, December 12 to “Hold” rating. The company was maintained on Wednesday, October 25 by RBC Capital Markets. The rating was maintained by SunTrust with “Buy” on Friday, October 13. Wedbush upgraded the shares of ONCE in report on Tuesday, December 12 to “Hold” rating. The firm has “Buy” rating by Mizuho given on Monday, February 12. J.P. Morgan maintained the shares of ONCE in report on Monday, December 11 with “Buy” rating.

Investors sentiment increased to 2.94 in Q3 2017. Its up 1.13, from 1.81 in 2017Q2. It is positive, as 17 investors sold Spark Therapeutics, Inc. shares while 19 reduced holdings. 46 funds opened positions while 60 raised stakes. 33.64 million shares or 23.59% more from 27.22 million shares in 2017Q2 were reported. Tekla Mngmt Limited Com reported 24,300 shares or 0.08% of all its holdings. Sg Americas accumulated 0.01% or 17,113 shares. Eventide Asset Ltd Liability Company holds 1.64% or 324,000 shares in its portfolio. 11,089 are owned by Cornerstone Capital Hldgs Ltd Liability Company. State Board Of Administration Of Florida Retirement Sys accumulated 10,064 shares. 700 are held by Pnc Fincl. Raymond James Assoc reported 0% stake. Rmb Cap Mngmt Ltd Limited Liability Company owns 10,940 shares. Dekabank Deutsche Girozentrale accumulated 0.01% or 13,800 shares. Wells Fargo And Communications Mn has invested 0.01% of its portfolio in Spark Therapeutics, Inc. (NASDAQ:ONCE). Fred Alger Management Inc invested 0.01% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Envestnet Asset Management Inc holds 0% or 164 shares in its portfolio. Legal And General Gru Plc holds 11,750 shares or 0% of its portfolio. 64 are owned by Meeder Asset Mgmt Inc. Tiaa Cref Inv Limited Liability Com holds 78,957 shares.

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company has market cap of $2.02 billion. The Company’s products include voretigene neparvovec, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or biallelic mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. It currently has negative earnings. The company's products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A.

The stock 0.35% or $0 during the last trading session, reaching $0.98. It is down 22.01% since February 17, 2017 and is downtrending. It has underperformed by 38.71% the S&P500.

Leave a Reply

Your email address will not be published. Required fields are marked *